SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.53+4.5%Nov 25 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (8264)5/5/2003 11:26:24 PM
From: NeuroInvestment  Read Replies (1) of 52153
 
What caught my eye--beyond the simple humanity of the approval--is the fact that McCLellan put himself out in front of it publicly. He's been making the right comments in interviews about not hindering the progress of useful drugs, so if this is his way of heralding his willingness to push that agenda inhouse, that would be very good news indeed.

Accelerated approvals with an emphasis upon Phase IV evaluation of clinical utility....that's just almost too reasonable to be true. Hope someone has told Russell Katz (CNS Division) that there's a new sheriff in town.

Harry Tracy
NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News